Ocugen, Inc.

OCGN

US67577C1053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:30:00 07/03/2026 am IST			5-day change	1st Jan Change
1.610 ^USD	-7.47%		-11.54%	+19.26%

04/03	Ocugen, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
04/03	Ocugen, Inc., Q4 2025 Earnings Call, Mar 04, 2026

Ocugen announces positive preliminary phase 2 data from Ocu410 modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration

Published on 01/15/2026 at 06:49 pm IST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Ocugen, Inc.

04/03	Ocugen, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
04/03	Ocugen, Inc., Q4 2025 Earnings Call, Mar 04, 2026
02/03	Ocugen Announces Phase 3 Limelight Enrollment Completion for Ocu400, A Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa	CI
09/02	Ocugen, Inc. Announces Executive Changes, Effective February 9, 2026	CI
09/02	Ocugen Names Rita Johnson-Greene as CFO	MT
09/02	Ocugen appoints Rita Johnson-Greene to chief financial officer	RE
09/02	Ocugen, Inc. Appoints Rita Johnson-Greene as Chief Financial Officer	CI
23/01	Ocugen Closes $20.9 Million Registered Direct Offering	MT
21/01	Ocugen Prices $22.5 Million Stock Offering	MT
21/01	Ocugen announces pricing of $22.5 million offering of common stock	RE
15/01	Ocugen, Inc. - Special Call
15/01	Ocugen Says Gene Therapy Reduced Lesion Growth by 46% in Eye Disease Trial	MT
15/01	Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration	CI
15/01	Ocugen announces positive preliminary phase 2 data from Ocu410 modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration	RE
06/11	Ocugen, Inc., Q3 2025 Earnings Call, Nov 05, 2025

Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.

Employees

Sector

Biotechnology & Medical Research

More about the company